Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
15.43
+0.28 (1.85%)
At close: Jan 7, 2026, 4:00 PM EST
15.48
+0.05 (0.32%)
After-hours: Jan 7, 2026, 6:30 PM EST
Wave Life Sciences Revenue
Wave Life Sciences had revenue of $7.61M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $109.23M, up 103.75% year-over-year. In the year 2024, Wave Life Sciences had annual revenue of $108.30M, down -4.42%.
Revenue (ttm)
$109.23M
Revenue Growth
+103.75%
P/S Ratio
22.75
Revenue / Employee
$379,271
Employees
288
Market Cap
2.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
| Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
| Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
| Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
| Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
| Dec 31, 2019 | 15.98M | 1.57M | 10.89% |
| Dec 31, 2018 | 14.41M | 10.52M | 270.25% |
| Dec 31, 2017 | 3.89M | 2.41M | 162.15% |
| Dec 31, 2016 | 1.49M | 1.33M | 876.97% |
| Dec 31, 2015 | 152.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
WVE News
- 2 days ago - Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 23 days ago - Why Did Wave Life Sciences Surge 147%? - Forbes
- 4 weeks ago - Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - What's Going On With Wave Life Sciences Stock Tuesday? - Benzinga
- 4 weeks ago - Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript - Seeking Alpha
- 4 weeks ago - Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss - GlobeNewsWire
- 4 weeks ago - Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - GlobeNewsWire